Maxim Positive on Onconova Therapeutics (ONTX) Following Q2 Report; Notes Accelerating INSPIRE Enrollment

August 15, 2016 2:53 PM EDT
Get Alerts ONTX Hot Sheet
Price: $2.48 +2.90%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ONTX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Maxim affirms Onconova Therapeutics (NASDAQ: ONTX) at Buy with a price target of $6 following Q2 results and update issued Monday.

Analyst Jason McCarthy noted the following key points today:

  • Onconova reported 2Q16 with revenues of $2.2M and a net loss of $5.4M. The company ended the period with $12.8M in cash. Combined with net proceeds of $15.8M from a July financing, Onconova has $27.6M in cash on the balance sheet, sufficient capital to fund the remainder of the phase III pivotal study of Rigosertib in high-risk MDS (Myelodysplastic Syndromes, "INSPIRE", data expected 2018).
  • INSPIRE (N=225) enrollment continues to accelerate as nearly two-thirds of the expected 135 sites are now on-line. Enrollment is expected to complete in 2017 and an interim look at the data (88 events) is expected in 2H17.
  • Conclusion. We see Onconova as funded across multiple inflection (data) points over the next year. The stock is trading at a "distressed" valuation, stemming from a disconnect between prior study failures and the current intelligent trial design. As such we believe Onconova remains a good value play for investors.

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment